Mizuho Forecasts Strong Price Appreciation for Chemours (NYSE:CC) Stock

Chemours (NYSE:CC) had its target price boosted by equities researchers at Mizuho from $17.00 to $21.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the specialty chemicals company’s stock. Mizuho’s target price would suggest a potential upside of 27.74% from the company’s current price.

Several other equities analysts have also weighed in on the stock. Morgan Stanley boosted their target price on shares of Chemours from $15.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 23rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a research note on Wednesday, January 21st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of Chemours in a research note on Friday, January 16th. Jefferies Financial Group reiterated a “hold” rating and issued a $17.00 price target on shares of Chemours in a research note on Monday, February 23rd. Finally, The Goldman Sachs Group upped their price objective on Chemours from $14.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $18.40.

Chemours Price Performance

Shares of NYSE CC opened at $16.44 on Thursday. Chemours has a 12 month low of $9.13 and a 12 month high of $21.85. The company has a debt-to-equity ratio of 16.33, a current ratio of 1.78 and a quick ratio of 0.85. The firm’s 50 day simple moving average is $16.38 and its 200-day simple moving average is $14.74. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -6.63 and a beta of 1.60.

Chemours (NYSE:CC) last announced its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter last year, the firm posted $0.09 EPS. The business’s revenue was down 2.2% on a year-over-year basis. Analysts expect that Chemours will post 2.03 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Chemours by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock valued at $211,287,000 after buying an additional 490,778 shares in the last quarter. State Street Corp grew its position in Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after acquiring an additional 1,131,682 shares during the period. Ameriprise Financial Inc. increased its position in Chemours by 13.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock worth $75,971,000 after purchasing an additional 580,089 shares in the last quarter. UBS Group AG increased its position in shares of Chemours by 0.3% in the third quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock worth $75,311,000 after acquiring an additional 14,865 shares in the last quarter. Finally, Cooper Creek Partners Management LLC acquired a new stake in Chemours in the 3rd quarter valued at $63,103,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Mizuho raised its price target to $21 and moved to an “outperform” rating, signaling analyst confidence in upside vs. the recent share level. Mizuho Raises CC Price Target
• Neutral Sentiment: Zacks issued a longer-term FY2028 EPS projection of $2.50, suggesting some expectation of recovery further out even as near-term estimates were cut.
• Neutral Sentiment: Most recent quarterly results showed a modest EPS beat but declining revenue and a negative net margin — a mixed operational picture that leaves guidance and margins the key watchables for investors.
• Negative Sentiment: Zacks Research broadly trimmed near-term estimates across multiple quarters and years: notable cuts include Q1 2026 from $0.20 to ($0.09), Q4 2026 from $0.29 to $0.13, FY2026 from $1.75 to $1.06, and FY2027 from $2.30 to $1.97. These downgrades lower near-term earnings expectations and increase downside risk to the stock if results follow the weaker outlook.
• Negative Sentiment: Pomerantz LLP announced an investor alert investigating claims on behalf of Chemours investors, which can create legal overhang and sentiment pressure until any resolution or further detail emerges. Pomerantz Investor Alert

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.